Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

18.31B

Market cap18.31B

Price-Earnings ratio

12.71

Price-Earnings ratio12.71

Dividend yield

—

Dividend yield—

Average volume

1.11M

Average volume1.11M

High today

$129.99

High today$129.99

Low today

$124.36

Low today$124.36

Open price

$129.21

Open price$129.21

Volume

1.52M

Volume1.52M

52 Week high

$236.48

52 Week high$236.48

52 Week low

$110.04

52 Week low$110.04

BIIB News

TipRanks 2d

Biogen Executive Makes Significant Stock Sale

New insider activity at Biogen ( (BIIB) ) has taken place on July 16, 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Un...

TipRanks 4d

Biogen’s New Study on Omaveloxolone for Young FA Patients: Market Insights

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

Analyst ratings

49%

of 37 ratings

Buy

48.6%

Hold

48.6%

Sell

2.7%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.